<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609295</url>
  </required_header>
  <id_info>
    <org_study_id>HP-ALA-hyperchol</org_study_id>
    <nct_id>NCT02609295</nct_id>
  </id_info>
  <brief_title>Effects of α-linolenic Acid Supplementation on Hemostasis in Nondiabetic and Hypercholesterolemic Subjects</brief_title>
  <official_title>Effects of α-linolenic Acid Supplementation in the Form of Perilla Oil on Collagen-epinephrine Closure Time, Activated Partial Thromboplastin Time and Lp-PLA2 Activities in Nondiabetic and Hypercholesterolemic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether ALA intake alters total cholesterol and homeostatic factors and
      the relationship between these alteration and lipoprotein associated phospholipase A2
      (Lp-PLA2) activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An 8-week, randomized, double-blind, placebo-controlled study was conducted with 86
      nondiabetic and borderline-to-moderate hypercholesterolemic (200mg/dL ≤ serum cholesterol ≤
      300mg/dL) subjects, not taking any medications and supplements to affect lipid metabolism,
      platelet function and inflammation, divided into two groups: an α-linolenic acid (ALA) group
      [1.2 g (two capsules) of perilla oil daily; 497 mg ALA] and a placebo group (1.2 g of
      medium-chain triglyceride oil daily).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Collagen-Epinephrine Closure Time (C-EPI CT)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Collagen-Epinephrine Closure Time (C-EPI CT)</measure>
    <time_frame>8-week follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prothrombin Time (PT)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin Time (PT)</measure>
    <time_frame>8-week follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time (aPTT)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time (aPTT)</measure>
    <time_frame>8-week follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen</measure>
    <time_frame>8-week follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals who consumed 1.2 g (two capsules) of medium-chain triglyceride (MCT) oil daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals who consumed 1.2 g (two capsules) of perilla oil daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1.2 g (two capsules) of medium-chain triglyceride (MCT) oil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ALA group</intervention_name>
    <description>1.2 g (two capsules) of perilla oil</description>
    <arm_group_label>ALA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntarily agree to participate and sign in informed consent form

          -  Adults aged 40-70

          -  Nondiabetic and hypercholesterolemic subjects (serum cholesterol ≥ 200 mg/dL)

        Exclusion Criteria:

          -  Subjects taking any medication or supplements known to affect lipid metabolism or
             platelet function, n-3 fatty acid supplementation or n-3 fatty acid-rich fish more
             than two times per week

          -  Following diseases: dyslipidemia, hypertension, diabetes, liver disease, renal
             disease, pancreatitis, cardiovascular disease, gastrointestinal disease, cancer, or
             any other disease requiring treatment

          -  Participation in clinical trials of any drug or supplement within 30 days prior to the
             participation of the study

          -  Pregnant or lactating women, alcoholic, mental patient

          -  Judged to be inappropriate for the study by the investigator after reviewing other
             reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yonsei University</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>α-linolenic acid</keyword>
  <keyword>perilla oil</keyword>
  <keyword>aPTT</keyword>
  <keyword>Collagen-epinephrine closure time</keyword>
  <keyword>Lp-PLA2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Perilla seed oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

